Privia Health Group Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
PRVA$24.37-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| (in thousands except share amounts) | Common Stock Shares | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Equity attributable to Privia Health Group, Inc. | Non-controlling Interest | Total Stockholders’ Equity |
|---|---|---|---|---|---|---|---|
| Balance at December 31, 2022 | 114,690,808 | $1,148 | $714,639 | $(216,693) | $499,094 | $19,955 | $519,049 |
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 779,153 | 11 | 1,466 | — | 1,477 | — | 1,477 |
| Stock-based compensation expense | — | — | 5,381 | — | 5,381 | — | 5,381 |
| Contributed non-controlling interest | — | — | — | — | — | 24,212 | 24,212 |
| Net income (loss) | — | — | — | 7,324 | 7,324 | (922) | 6,402 |
| Balance at March 31, 2023 | 115,469,961 | 1,159 | 721,486 | (209,369) | 513,276 | 43,245 | 556,521 |
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 1,636,931 | 12 | 4,294 | — | 4,306 | — | 4,306 |
| Stock-based compensation expense | — | — | 9,247 | — | 9,247 | — | 9,247 |
| Repurchase of non-controlling interest | — | — | (8,871) | — | (8,871) | 3,177 | (5,694) |
| Contributed non-controlling interest | — | — | — | — | — | 569 | 569 |
| Net income (loss) | — | — | — | 7,274 | 7,274 | (914) | 6,360 |
| Balance at June 30, 2023 | 117,106,892 | 1,171 | 726,156 | (202,095) | 525,232 | 46,077 | 571,309 |
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 897,652 | 9 | 2,996 | — | 3,005 | — | 3,005 |
| Stock-based compensation expense | — | — | 10,801 | — | 10,801 | — | 10,801 |
| Net income | — | — | — | 5,643 | 5,643 | 299 | 5,942 |
| Balance at September 30, 2023 | 118,004,544 | $1,180 | $739,953 | $(196,452) | $544,681 | $46,376 | $591,057 |
| Balance at December 31, 2023 | 118,216,979 | $1,182 | $753,869 | $(193,614) | $561,437 | $45,952 | $607,389 |
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 461,923 | 5 | 470 | — | 475 | — | 475 |
| Stock-based compensation expense | — | — | 11,904 | — | 11,904 | — | 11,904 |
| Net income | — | — | — | 2,984 | 2,984 | 72 | 3,056 |
| Balance at March 31, 2024 | 118,678,902 | 1,187 | 766,243 | (190,630) | 576,800 | 46,024 | 622,824 |
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 800,232 | 7 | 742 | — | 749 | — | 749 |
| Stock-based compensation expense | — | — | 14,391 | — | 14,391 | — | 14,391 |
| Contributed non-controlling interest | — | — | — | — | — | 1,000 | 1,000 |
| Net income | — | — | — | 3,467 | 3,467 | 1,176 | 4,643 |
| Balance at June 30, 2024 | 119,479,134 | 1,194 | $781,376 | (187,163) | 595,407 | 48,200 | 643,607 |
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 474,042 | 5 | 833 | — | 838 | — | 838 |
| Stock-based compensation expense | — | — | 15,106 | — | 15,106 | — | 15,106 |
| Contributed non-controlling interest | — | — | — | — | — | 653 | 653 |
| Distribution to non-controlling interest | — | — | — | — | — | (2,000) | (2,000) |
| Net income | — | — | — | 3,535 | 3,535 | 443 | 3,978 |
| Balance at September 30, 2024 | 119,953,176 | $1,199 | $797,315 | $(183,628) | $614,886 | $47,296 | $662,182 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.